1. RAMQ – Liste des médicaments, version du 14 décembre 2022. https://www.ramq.gouv.qc.ca/sites/default/files/documents/liste_med_2022-12-14_fr.pdf. Consulté le 15 décembre 2022
2. Novo Nordisk Canada Inc. Monographie de Saxenda. 21 juillet 2017
3. Novo Nordisk Canada Inc. Monographie de Wegovy. 23 novembre 2021.
4. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. New England Journal of Medicine. 2022;387(12):1089-1098. doi:10.1056/NEJMoa2206286
5. MacKay D, Chan C, Dasgupta K, et al. Remission of Type 2 Diabetes. Canadian Journal of Diabetes. 2022;46(8):753-761.e8. doi:10.1016/j.jcjd.2022.10.004
6. Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. The Lancet. 2022;399(10322):394-405. doi:10.1016/S0140-6736(21)01919-X
7. EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. Published online November 4, 2022. doi:10.1056/NEJMoa2204233
8. Wheeler DC, Stefánsson BV, Jongs N, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. The Lancet Diabetes & Endocrinology. 2021;9(1):22-31. doi:10.1016/S2213-8587(20)30369-7
9. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. The Lancet Diabetes & Endocrinology. 2021;9(10):653-662. doi:10.1016/S2213-8587(21)00203-5
10. Fondation des maladies du cœur du Canada. Insuffisance cardiaque. Accessible au https://www.coeuretavc.ca/maladies-du-coeur/problemes-de-sante/insuffisance-cardiaque. Consulté le 29 novembre 2021
11. Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385(24):2252-2263. doi:10.1056/NEJMoa2110956
12. McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA Cardiol. 2021;6(2):148-158. doi:10.1001/jamacardio.2020.4511
13. McDonald M, Virani S, Chan M, et al. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. Canadian Journal of Cardiology. 2021;37(4):531-546. doi:10.1016/j.cjca.2021.01.017
14. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special

contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368
15. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276. doi:10.1016/j.kint.2021.05.021
16. Caleyachetty R, Barber TM, Mohammed NI, et al. Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study. The Lancet Diabetes & Endocrinology. 2021;9(7):419-426. doi:10.1016/S2213-8587(21)00088-7
17. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine. 2021;0(0):null. doi:10.1056/NEJMoa2107038
18. Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. CMAJ. 2020;192(31):E875-E891. doi:10.1503/cmaj.191707
19. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190
20. Martinez Felipe A., Serenelli Matteo, Nicolau Jose C., et al. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age. Circulation. 2020;141(2):100-111. doi:10.1161/CIRCULATIONAHA.119.044133
21. Lipscombe L, Butalia S, Dasgupta K, et al. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update. Canadian Journal of Diabetes. 2020;44(7):575-591. doi:10.1016/j.jcjd.2020.08.001
22. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342-1356. doi:10.1002/ejhf.1858
23. Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2020;17(9):559-573. doi:10.1038/s41569-020-0363-2
24. Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2020;383(23):2219-2229. doi:10.1056/NEJMoa2025845
25. Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal. 2019;40(40):3297-3317. doi:10.1093/eurheartj/ehz641
26. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. Published online September 19, 2019. doi:10.1056/NEJMoa1911303
27. Tobe SW, Gilbert RE, Jones C, Leiter LA, Prebtani APH, Woo V. Treatment of Hypertension. Canadian Journal of Diabetes. 2018;42:S186-S189. doi:10.1016/j.jcjd.2017.10.011
28. Solomon SD, Rizkala AR, Lefkowitz MP, et al. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circulation: Heart Failure. 2018;11(7):e004962. doi:10.1161/CIRCHEARTFAILURE.118.004962

29. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018;138(9):861-870. doi:10.1161/CIRCULATIONAHA.118.034646
30. Jardine MJ, Mahaffey KW, Neal B, et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. Am J Nephrol. 2018;46(6):462-472. doi:10.1159/000484633
31. Diabetes Canada Clinical Practice Guidelines Expert Committee, Meneilly GS, Knip A, et al. Diabetes in Older People. Can J Diabetes. 2018;42 Suppl 1:S283-S295. doi:10.1016/j.jcjd.2017.10.021
32. Diabetes Canada Clinical Practice Guidelines Expert Committee, McFarlane P, Cherney D, Gilbert RE, Senior P. Chronic Kidney Disease in Diabetes. Can J Diabetes. 2018;42 Suppl 1:S201-S209. doi:10.1016/j.jcjd.2017.11.004
33. Canada A de la santé publique du. Rapport du Système canadien de surveillance des maladies chroniques : Les maladies du cœur au Canada, 2018. Published May 7, 2018. Accessed April 6, 2023. https://www.canada.ca/fr/sante-publique/services/publications/maladies-et-affections/rapport-maladies-coeur-canada-2018.html
34. Shah KS, Xu H, Matsouaka RA, et al. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction. Journal of the American College of Cardiology. 2017;70(20):2476-2486. doi:10.1016/j.jacc.2017.08.074
35. Kazlauskaite R, Avery-Mamer EF, Li H, et al. Race/ethnic comparisons of waist-to-height ratio for cardiometabolic screening: The study of women's health across the nation. Am J Hum Biol. 2017;29(1). doi:10.1002/ajhb.22909
36. Ezekowitz JA, O'Meara E, McDonald MA, et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Canadian Journal of Cardiology. 2017;33(11):1342-1433. doi:10.1016/j.cjca.2017.08.022
37. Crespo-Leiro MG, Anker SD, Maggioni AP, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. European Journal of Heart Failure. 2016;18(6):613-625. doi:10.1002/ejhf.566
38. Cherney DZI, Udell JA. Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility. Circulation. 2016;134(24):1915-1917. doi:10.1161/CIRCULATIONAHA.116.024764
39. Mavrea AM, Dragomir T, Bordejevic DA, Tomescu MC, Ancusa O, Marincu I. Causes and predictors of hospital readmissions in patients older than 65 years hospitalized for heart failure with preserved left ventricular ejection fraction in western Romania. CIA. 2015;10:979-990. doi:10.2147/CIA.S83750
40. McMurray JJV, Packer M, Desai AS, et al. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. New England Journal of Medicine. 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077
41. Chapter 2: Definition, identification, and prediction of CKD progression. Kidney International Supplements. 2013;3(1):63-72. doi:10.1038/kisup.2012.65
42. Zakeri R, Chamberlain AM, Roger VL, Redfield MM. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a

community-based study. Circulation. 2013;128(10):1085-1093. doi:10.1161/CIRCULATIONAHA.113.001475
43. Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2013;10(4):401-410. doi:10.1007/s11897-013-0155-7
44. Ashwell M, Gunn P, Gibson S. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. Obes Rev. 2012;13(3):275-286. doi:10.1111/j.1467-789X.2011.00952.x
45. Browning LM, Hsieh SD, Ashwell M. A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 0·5 could be a suitable global boundary value. Nutr Res Rev. 2010;23(2):247-269. doi:10.1017/s0954422410000144
46. Bays HE, González-Campoy JM, Henry RR, et al. Is adiposopathy (sick fat) an endocrine disease? International Journal of Clinical Practice. 2008;62(10):1474-1483. doi:10.1111/j.1742-1241.2008.01848.x
47. Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50(8):768-777. doi:10.1016/j.jacc.2007.04.064
48. Lenzen M. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. European Heart Journal. 2004;25(14):1214-1220. doi:10.1016/j.ehj.2004.06.006